Related Experiment Video
Updated: Jul 30, 2025

Intracellular Refolding Assay
Published on: January 24, 2012
Poor Result Reporting Rate in Cell Therapy Trials Registered at ClinicalTrials.gov
Takaharu Negoro1,2, Hanayuki Okura1,2, Shigekazu Hayashi1
1Center for Reverse Translational Research, Osaka Habikino Medical Center, Osaka Prefectural Hospital Organization, Habikino City, Japan.
Abstract:
As research associates in clinical experiments, we have an obligation to disclose clinical methodologies and findings in full transparency in ethics. However, inadequate disclosure in results reporting clinical trials registered on ClinicalTrials.gov has been revealed, with approximately half the trial results not being reported in an applicable manner. Our recent study in clinical trials of regenerative medicine for four kinds of neurological diseases revealed that the rate of result reporting to ClinicalTrials.gov is inadequate for gene and cell therapy (CT) trials. In this path, further curiosity emerged to see what the findings would be if the analysis was conducted for trials in all disease areas, and outcomes if gene therapy (GT) and CT were distinguished in terms. In this study, the scope of analysis was further expanded to include all disease areas, and the drug classification from the AdisInsight database was used for modality classification, with biologic drug trials classified as controls, CT, ex vivo GT, and in vivo GT. To begin, among all interventional clinical trials with registration in the ClinicalTrials.gov registry and with a primary completion between 2010 and 2019, we created a total of 5539 datasets corresponding to trials classified as GT and CT, while biologics (BLG) as controls in the AdisInsight drug classification. The status of reported results of these trials was identified by surveying posting status of ClinicalTrials.gov and publication in journals (PubMed), respectively. Based on the obtained dataset, multivariate analysis was performed on the data on the reporting rate of clinical trial results, aggregated by sponsor, phase, status, and modality (CT, ex vivo GT, in vivo GT, and BLG), respectively. The result shows that CT was identified as an independent factor restraining result reporting ratio in both ClinicalTrials.gov and total disclosures, whereas ex vivo GT as boosting result reporting ratio. Since the result reporting rate of CT results was notably poor, we discussed the causes and solutions in this regard.
Insights
Clinical trial result reporting is inadequate, especially for cell and gene therapy (CTGT) trials. Cell and gene therapy trials show lower reporting rates, while ex vivo gene therapy trials demonstrate higher rates. Solutions are needed to improve transparency.
Area of Science:
- Clinical research transparency
- Biomedical data reporting
- Health outcomes research
Background:
- Ethical obligations require full disclosure of clinical trial methodologies and findings.
- Previous studies indicated inadequate reporting of clinical trial results on ClinicalTrials.gov, with about half of trials not reported appropriately.
- A prior study highlighted insufficient result reporting for gene and cell therapy (CT) trials in regenerative medicine.
Purpose of the Study:
- To assess the reporting rates of clinical trial results across all disease areas, distinguishing between gene therapy (GT) and cell therapy (CT).
- To analyze the impact of different therapeutic modalities (biologics, CT, ex vivo GT, in vivo GT) on result reporting.
- To identify factors influencing the reporting of clinical trial outcomes on ClinicalTrials.gov and in publications.
Main Methods:
- Analysis of 5539 interventional clinical trials registered on ClinicalTrials.gov (2010-2019) classified by AdisInsight database as biologics (BLG), CT, ex vivo GT, and in vivo GT.
- Assessment of result reporting status through ClinicalTrials.gov posting and PubMed publication.
- Multivariate analysis of reporting rates based on sponsor, phase, status, and modality.
Main Results:
- Cell and gene therapy (CT) was identified as a significant factor associated with lower result reporting ratios on both ClinicalTrials.gov and in total disclosures.
- Ex vivo gene therapy (GT) was associated with a higher result reporting ratio.
- The overall reporting rate for CT trials was notably poor, necessitating further investigation.
Conclusions:
- Cell and gene therapy (CT) trials exhibit a concerningly low rate of results disclosure, impacting overall clinical research transparency.
- Ex vivo gene therapy (GT) demonstrates a positive association with improved result reporting.
- Addressing the underreporting in CT trials is crucial for ethical research practices and requires exploring underlying causes and potential solutions.
Related Concept Videos
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against...
EPS and iPS Cells in Disease Research

